Your browser is no longer supported. Please, upgrade your browser.
NTLA [NASD]
Intellia Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.28 Insider Own1.40% Shs Outstand58.75M Perf Week-7.38%
Market Cap3.47B Forward P/E- EPS next Y-2.98 Insider Trans-43.37% Shs Float52.88M Perf Month-10.76%
Income-120.30M PEG- EPS next Q-0.60 Inst Own92.60% Short Float16.21% Perf Quarter97.03%
Sales62.30M P/S55.62 EPS this Y-6.30% Inst Trans7.41% Short Ratio4.94 Perf Half Y215.45%
Book/sh5.61 P/B11.36 EPS next Y-30.70% ROA-30.10% Target Price74.58 Perf Year425.74%
Cash/sh7.50 P/C8.49 EPS next 5Y30.00% ROE-40.10% 52W Range9.18 - 92.00 Perf YTD17.13%
Dividend- P/FCF- EPS past 5Y-50.60% ROI- 52W High-30.01% Beta2.03
Dividend %- Quick Ratio7.50 Sales past 5Y- Gross Margin- 52W Low601.42% ATR6.24
Employees270 Current Ratio7.50 Sales Q/Q109.40% Oper. Margin- RSI (14)46.00 Volatility9.84% 8.74%
OptionableYes Debt/Eq0.00 EPS Q/Q2.70% Profit Margin- Rel Volume0.89 Prev Close63.72
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 BMO Payout- Avg Volume1.74M Price64.39
Recom2.20 SMA20-4.38% SMA50-3.12% SMA20086.85% Volume314,595 Change1.05%
Dec-22-20Downgrade Robert W. Baird Outperform → Neutral $60
Oct-27-20Initiated Truist Buy $40
Oct-14-20Initiated Wells Fargo Overweight
Sep-18-20Initiated Goldman Buy $33
Feb-28-20Upgrade Oppenheimer Perform → Outperform
Feb-14-20Downgrade Wedbush Outperform → Neutral $16
Nov-01-19Upgrade Raymond James Mkt Perform → Outperform
Jul-09-19Initiated Robert W. Baird Outperform $23
Jun-10-19Initiated ROTH Capital Neutral $16
May-03-19Upgrade Wedbush Neutral → Outperform $20 → $21
Apr-12-19Initiated Evercore ISI Outperform
Nov-02-18Downgrade Wedbush Outperform → Neutral $36 → $20
Oct-29-18Initiated Credit Suisse Neutral $24
Sep-21-18Initiated Raymond James Mkt Perform
May-15-18Upgrade Chardan Capital Markets Neutral → Buy $20 → $57.50
Mar-08-18Initiated JMP Securities Mkt Outperform $76
Nov-01-17Reiterated Jefferies Buy $36 → $42
Jun-22-17Resumed Jefferies Buy $36
Mar-28-17Initiated Chardan Capital Markets Buy $19
Aug-05-16Upgrade Jefferies Hold → Buy
Feb-25-21 07:30AM  
05:45AM  
Feb-18-21 07:30AM  
Jan-29-21 09:44AM  
Jan-20-21 08:23AM  
Jan-15-21 06:12PM  
Jan-14-21 03:11PM  
Jan-11-21 08:02AM  
Jan-08-21 09:01AM  
Jan-07-21 04:24PM  
01:05PM  
08:42AM  
07:30AM  
Jan-06-21 11:00AM  
Jan-04-21 09:27AM  
Jan-01-21 01:22AM  
Dec-30-20 10:42AM  
Dec-29-20 12:27PM  
09:37AM  
Dec-21-20 04:24PM  
Dec-16-20 09:33PM  
Dec-12-20 09:00AM  
Dec-10-20 02:03PM  
Dec-09-20 11:06AM  
Dec-07-20 04:20PM  
Dec-05-20 10:00AM  
Dec-04-20 04:01PM  
08:00AM  
Dec-03-20 08:41AM  
Dec-01-20 09:30PM  
Nov-30-20 04:01PM  
Nov-11-20 07:30AM  
Nov-09-20 07:30AM  
05:57AM  
Nov-06-20 05:30PM  
Nov-05-20 07:30AM  
06:15AM  
Oct-29-20 07:30AM  
Oct-27-20 10:35AM  
Oct-19-20 07:30AM  
Oct-07-20 04:20PM  
10:04AM  
Oct-05-20 07:30AM  
Sep-29-20 08:20AM  
Sep-28-20 08:00AM  
Sep-22-20 09:43AM  
Sep-18-20 09:31AM  
Sep-02-20 08:00AM  
Aug-11-20 11:10AM  
11:06AM  
Aug-06-20 09:15AM  
07:30AM  
Aug-03-20 08:00AM  
Jul-30-20 12:33PM  
07:30AM  
Jul-25-20 11:52AM  
Jul-14-20 07:07AM  
Jul-05-20 10:52PM  
Jul-02-20 11:32AM  
Jun-10-20 11:48PM  
Jun-05-20 04:01PM  
12:37AM  
Jun-03-20 09:56AM  
07:54AM  
07:02AM  
Jun-02-20 09:00PM  
11:09AM  
09:15AM  
07:45AM  
02:35AM  
Jun-01-20 04:00PM  
11:46AM  
07:57AM  
07:00AM  
May-22-20 07:39AM  
May-18-20 07:12PM  
May-12-20 06:00AM  
May-11-20 07:43AM  
May-09-20 01:31PM  
May-07-20 09:15AM  
08:38AM  
07:30AM  
Apr-30-20 12:34PM  
07:50AM  
07:30AM  
Apr-28-20 04:30PM  
Apr-13-20 12:00PM  
Apr-06-20 06:26PM  
Mar-31-20 07:30AM  
Mar-24-20 04:19PM  
Feb-27-20 08:55AM  
07:30AM  
Feb-20-20 10:53AM  
07:30AM  
Feb-19-20 12:31PM  
Feb-12-20 09:33AM  
Feb-10-20 07:30AM  
Feb-07-20 08:54AM  
Jan-17-20 02:09PM  
Jan-09-20 07:30AM  
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEONARD JOHN MPresident and CEOFeb 09Option Exercise6.8356,718387,384688,579Feb 09 08:36 PM
Rivera Jose EEVP, General CounselFeb 09Option Exercise18.3021,000384,195129,409Feb 09 08:38 PM
Rivera Jose EEVP, General CounselFeb 09Sale75.0011,489861,675117,920Feb 09 08:38 PM
LEONARD JOHN MPresident and CEOFeb 09Sale75.0028,0432,103,225660,536Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 05Option Exercise13.4040,000536,000654,803Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 05Sale67.6622,9421,552,185631,861Feb 09 08:36 PM
LEONARD JOHN MPresident and CEOFeb 03Option Exercise17.68117,0602,069,793651,661Feb 03 09:39 PM
LEONARD JOHN MPresident and CEOFeb 03Sale72.5467,8564,922,490584,601Feb 03 09:39 PM
Rivera Jose EEVP, General CounselFeb 01Option Exercise9.68109,0001,054,620121,686Feb 03 09:38 PM
LEONARD JOHN MPresident and CEOFeb 01Option Exercise13.69200,0002,737,600598,814Feb 03 09:39 PM
LEONARD JOHN MPresident and CEOFeb 01Sale64.00109,8897,032,905523,853Feb 03 09:39 PM
Rivera Jose EEVP, General CounselFeb 01Sale63.9954,6593,497,90288,686Feb 03 09:38 PM
Cohen Fred EDirectorJan 20Option Exercise13.7820,000275,60030,000Jan 22 04:22 PM
LEONARD JOHN MPresident and CEOJan 05Sale55.866,239348,511475,488Jan 05 09:24 PM
Rivera Jose EEVP, General CounselJan 05Sale55.862,078116,07751,990Jan 05 08:55 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerJan 05Sale55.861,37776,91916,656Jan 05 08:58 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerDec 31Option Exercise0.004,792018,033Jan 05 08:58 PM
Rivera Jose EEVP, General CounselDec 31Option Exercise0.004,792054,068Jan 05 08:55 PM
LEONARD JOHN MPresident and CEODec 31Option Exercise0.0014,3750481,727Jan 05 09:24 PM
SCHIERMEIER ANDREWEVP, Chief Operating OfficerDec 30Option Exercise13.481,50020,22012,673Jan 04 09:03 PM
KARSEN PERRY ADirectorDec 17Option Exercise18.4588,7641,637,84293,764Dec 18 04:29 PM
KARSEN PERRY ADirectorDec 17Sale53.5588,7644,753,6805,000Dec 18 04:29 PM
Rivera Jose EEVP, General CounselDec 01Option Exercise13.885,00069,40052,072Dec 03 06:42 PM
Rivera Jose EEVP, General CounselDec 01Sale38.213,364128,52548,708Dec 03 06:42 PM
LEONARD JOHN MPresident and CEONov 27Option Exercise16.1735,000566,100487,352Nov 27 09:00 PM
LEONARD JOHN MPresident and CEONov 27Sale38.5735,0001,350,000467,352Nov 27 09:00 PM
LEONARD JOHN MPresident and CEONov 25Option Exercise6.8350,000341,500517,352Nov 25 08:02 PM
LEONARD JOHN MPresident and CEONov 25Sale36.0050,0001,800,000467,352Nov 25 08:02 PM
Rivera Jose EEVP, General CounselNov 18Option Exercise18.3084815,51847,696Nov 18 07:55 PM
Rivera Jose EEVP, General CounselNov 18Sale35.0062421,84047,072Nov 18 07:55 PM
Rivera Jose EEVP, General CounselNov 16Option Exercise7.4410,56278,58552,315Nov 18 07:55 PM
LEONARD JOHN MPresident and CEONov 16Option Exercise14.5820,000291,600487,352Nov 18 07:56 PM
LEONARD JOHN MPresident and CEONov 16Sale34.0020,000680,000467,352Nov 18 07:56 PM
Rivera Jose EEVP, General CounselNov 16Sale34.296,029206,72846,700Nov 18 07:55 PM
LEONARD JOHN MPresident and CEONov 04Option Exercise6.8350,000341,500517,352Nov 06 04:38 PM
Rivera Jose EEVP, General CounselNov 04Option Exercise13.885,00069,40045,679Nov 06 04:41 PM
LEONARD JOHN MPresident and CEONov 04Sale26.0050,0001,300,000467,352Nov 06 04:38 PM
Rivera Jose EEVP, General CounselNov 04Sale28.003,36494,19242,315Nov 06 04:41 PM
Rivera Jose EEVP, General CounselOct 15Option Exercise6.8310,00068,30046,294Oct 16 08:58 PM
Rivera Jose EEVP, General CounselOct 15Sale24.205,615135,88340,679Oct 16 08:58 PM
LEONARD JOHN MPresident and CEOOct 07Option Exercise6.835,00034,150472,352Oct 09 04:14 PM
LEONARD JOHN MPresident and CEOOct 07Sale21.835,000109,150467,352Oct 09 04:14 PM
Rivera Jose EEVP, General CounselSep 15Option Exercise6.8310,00068,30041,909Sep 17 04:55 PM
Rivera Jose EEVP, General CounselSep 15Sale21.045,615118,14036,294Sep 17 04:55 PM
LEONARD JOHN M.President and CEOSep 01Option Exercise6.835,00034,150472,352Sep 03 04:15 PM
LEONARD JOHN M.President and CEOSep 01Sale21.835,000109,150467,352Sep 03 04:15 PM
Rivera Jose EEVP, General CounselAug 18Option Exercise6.8310,00068,30037,524Aug 20 04:13 PM
Rivera Jose EEVP, General CounselAug 18Sale21.005,615117,91531,909Aug 20 04:13 PM
LEONARD JOHN M.President and CEOAug 06Option Exercise6.835,00034,150472,352Aug 07 07:29 PM
LEONARD JOHN M.President and CEOAug 06Sale21.835,000109,150467,352Aug 07 07:29 PM
Rivera Jose EEVP, General CounselJul 15Option Exercise6.8310,00068,30033,139Jul 17 04:18 PM
Rivera Jose EEVP, General CounselJul 15Sale22.705,615127,46027,524Jul 17 04:18 PM
LEONARD JOHN M.President and CEOJul 01Option Exercise6.835,00034,150472,352Jul 02 04:10 PM
LEONARD JOHN M.President and CEOJul 01Sale21.835,000109,150467,352Jul 02 04:10 PM
Rivera Jose EEVP, General CounselJun 16Option Exercise6.8310,00068,30027,897Jun 18 05:00 PM
Rivera Jose EEVP, General CounselJun 16Sale21.005,615117,91522,282Jun 18 05:00 PM
LEONARD JOHN M.President and CEOJun 03Option Exercise6.835,00034,150472,352Jun 05 05:18 PM
LEONARD JOHN M.President and CEOJun 03Sale21.835,000109,150467,352Jun 05 05:18 PM
Rivera Jose EEVP, General CounselMay 26Option Exercise6.8310,00068,300285,722May 28 05:23 PM
Rivera Jose EEVP, General CounselMay 26Sale21.215,615119,094280,107May 28 05:23 PM